HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings Ltd was incorporated in 2005 and is based in Jerusalem, Israel.
Stock data | 2024 | Change |
---|---|---|
Price | $0.0006797053728461671 | N/A |
Market Cap | $7.54K | N/A |
Shares Outstanding | 11.09M | N/A |
Employees | 2.00 | N/A |